Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer

Zhao Jianjie; Zhang Xiaohua; Hao Shuai; Luo Donglin

您当前的位置：

首页 >

文章列表页 >

Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer

更新时间：2023-12-22

- Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer
- Journal of Chongqing Medical University Vol. 44, Issue 12, Pages: 1542(2019)
- 作者机构：
  
  陆军军医大学大坪医院野战外科研究所乳腺甲状腺外科,重庆,40042
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2019，
扫描看全文
Zhao Jianjie, Zhang Xiaohua, Hao Shuai, et al. Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer. [J]. Journal of Chongqing Medical University 44(12):1542(2019)
DOI：

Zhao Jianjie, Zhang Xiaohua, Hao Shuai, et al. Progress in predictive markers of neoadjuvant endocrine therapy for ER+ breast cancer. [J]. Journal of Chongqing Medical University 44(12):1542(2019) DOI：

摘要

乳腺癌是全球范围内女性最常见的恶性肿瘤，极大地威胁广大患者的健康。新辅助治疗不仅能增加保乳手术的比例，还能对治疗的有效性进行体内敏感性测试。尤其是在三阴性和Her2过度表达的亚型中，病理完全缓解是患者长期预后良好的重要预测指标。然而，对于雌激素受体阳性乳腺癌，虽然大多数这种癌症亚型患者的总体预后良好，但因缺乏准确而便捷的疗效预测标志物，临床医生在新辅助内分泌治疗和新辅助化疗之间的决策缺乏可靠的依据。为减少盲目化疗所致的不必要副反应，亟需寻找新的新辅助内分泌治疗预测标志物。本文回顾了现有新辅助内分泌治疗雌激素受体阳性乳腺癌预后标志物的应用和局限性，以及新生物标记物的研究现状。

Abstract

Breast cancer is the most common malignant tumor of women in the world，which greatly threatens patients' health. Neoad－juvant therapy can not only increase the proportion of breast conserving surgery，but also can test internal sensitivity of treatments' efficacy. Especially in triple negative and Her-2 overexpression subtypes，pathological complete response is an important predictor of long-term prognosis. However，the overall prognosis of most patients with estrogen receptor（ER） positive breast cancer is good，but clinicians lack reliable evidence for decision-making between neoadjuvant endocrine therapy and neoadjuvant chemotherapy due to the lack of accurate and convenient predictors. In order to reduce side effects caused by unnecessary chemotherapy，it is urgent to find new predictive markers for neoadjuvant endocrine therapy. This paper reviewed applications and limitations of prognostic markers in current neoadjuvant endocrine therapy to treat ER+ breast cancer，and the current status of new biomarkers.

关键词

乳腺癌雌激素受体新辅助内分泌治疗预测因子

Keywords

breast cancerestrogen receptorneoadjuvant endocrine therapypredictive markers

references

Views

169

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

CORRELATION OF ESTROGEN RECEPTOR CONTENT AND MORPHOMETRIC ULTRA-STRUCTURE OF BREAST CANCER

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Effects of circular RNA hsa_circ_0002185 on cell viability and invasion of breast cancer cells and its mechanism of action

Prediction and identification of H-2Kd restricted CTL epitope derived from breast cancer associated antigen ROR1

Comparison of lung dosimetry between supine and sternal horizon positions during X-ray irradiated radical mastectomy radiation therapy

Related Author

Zhang Zhenhuan

et al

汪康莹

Zhang Jieqiu

Wu Qi

Wang Jianmei

Yao Xiaopeng

Shaojie Qin

Related Institution

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

Oncological Surgery Third Department, General Hospital of Ningxia Medical University

Department of Pathophysiology,College of Basic Medicine,Chongqing Medical University,Laboratory of Stem Cell and Tissue Engineering

⁰